Comparison of extracorporeal cellular therapy (ELAD^®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure

Zhongping Duan1 Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China, [email protected]Correspondence[email protected]

Shaojie Xin2 Department of Infectious Disease, Division III, 302 Military Hospital of China, Beijing, China, [email protected]Correspondence[email protected]

Jing Zhang1 Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China, [email protected]

Shaoli You2 Department of Infectious Disease, Division III, 302 Military Hospital of China, Beijing, China, [email protected]

Yu Chen1 Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China, [email protected]

Hongling Liu2 Department of Infectious Disease, Division III, 302 Military Hospital of China, Beijing, China, [email protected]

Sujun Zheng1 Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China, [email protected]

Zheng Li3 Research and Development, Vital Therapies, Inc, San Diego, CA, USA

Robert Ashley3 Research and Development, Vital Therapies, Inc, San Diego, CA, USA

Michael Millis4 Department of Surgery, University of Chicago, Chicago, IL, USA

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.